Heartflow, Inc. Common Stock

Heartflow, Inc. Common Stock Earnings Recaps

HTFL 2 recaps
Next earnings: March 17, 2027 (estimated) · full calendar
Q3 2026 Nov 14, 2026

HeartFlow’s shares fell 19.1% after earnings, despite raised full-year revenue and gross-margin guidance. The transcript does not identify a specific disappointment; management’s outlook was raised, so the selloff cannot be attributed to a guidance cut or a stated slowdown based on the available information.

Key takeaways
  • Q3 revenue was $72.9 million, up 57% year over year; U.S. revenue increased 60%.
  • Management raised full-year revenue guidance to $262 million–$264 million, or 49%–50% year-over-year growth, and Plaque revenue guidance to $36 million–$37 million.
  • Non-GAAP gross-margin guidance increased to approximately 82.5%; the company reiterated its midterm target of 85%.
  • HeartFlow expects approximately 1,300 Plaque-activated accounts by year-end, with Plaque coverage reaching about 82% of U.S. lives.
  • The company expects 2026 new account activations to exceed the 340 added in 2025.
Q2 2026 Aug 16, 2026

HeartFlow’s Q2 revenue growth and product utilization notably exceeded expectations, driving a 41% surge in the stock. Accelerating commercial adoption across both Plaque and FFRCT segments underpinned a meaningful upward revision in full-year guidance.

Key takeaways
  • Q2 revenue reached $64.1 million, up 48% year-over-year, marking the fastest growth in eight quarters, with U.S. revenue up 51%.
  • Full-year 2026 revenue guidance raised to $246 million–$250 million, a 40%–42% increase year-over-year; Plaque revenue guidance increased to $29 million–$31 million.
  • Non-GAAP gross margin guidance lifted to ~82%, benefiting from AI-driven efficiency, volume leverage, and higher Plaque revenue mix; maintaining mid-term target of 85%.
  • New account additions and physician utilization of both Plaque and FFRCT remained robust; the 340 accounts added in 2025 continue ramping in line with expectations.
  • Innovation pipeline progressing with launch of Plaque Staging and continued rollout of PCI Navigator, expected to support adoption into 2027.